Want to see TSE:FRX full AI Analyst Report?
FRX Stock Chart & Stats
C$13.95
-C$0.70(-4.78%)
At close: 4:00 PM EDT
C$13.95
-C$0.70(-4.78%)
Day’s Range― - ―
52-Week RangeC$7.59 - C$16.00
Previous CloseN/A
Volume1.00
Average Volume (3M)639.00
Market Cap
C$482.61M
Enterprise ValueC$178.44
Total Cash (Recent Filing)C$40.18M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 06, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding34,737,030
10 Day Avg. Volume82
30 Day Avg. Volume639
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.28
Price to Sales (P/S)4.93
P/FCF Ratio-17.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$21.73Price Target Upside55.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.36
Revenue Forecast (FY)C$94.15M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & High Gross MarginsSustained top-line acceleration and ~92% gross margins indicate PEDMARK has attractive product economics and scalable unit profitability. Six consecutive quarters of sales growth and a 73% YoY Q1 jump support durable adoption in eligible oncology settings, enabling reinvestment into commercialization.
Clean Balance Sheet & LiquidityZero debt and positive equity materially lower financial risk and preserve flexibility to fund growth. Management cites cash plus projected PEDMARK revenues as sufficient to execute the plan, giving runway for the commercial build without immediate refinancing over the next several quarters.
Commercial & HEARS Operational MomentumRapid HEARS hub volume growth and high conversion/adherence create a durable channel to capture and retain patients, improving lifetime product utilization. Combined with expanded prescriber targeting and new territories, these operational gains underpin sustainable revenue expansion as field productivity matures.
Bears Say
Persistent Cash BurnDespite quarter-level positive cash flow in Q1, TTM cash burn remains material and free cash flow worsened YoY. Continued negative cash generation over multiple quarters makes funding dependent on continued sales ramp or external financing, constraining flexibility during execution risks.
Ongoing Losses And Negative ROEPersistent net losses and deeply negative ROE signal shareholder capital is not yet producing returns. Extended unprofitability can erode equity over time and may force capital raises or reduced investment if revenue momentum slows, undermining long-term value creation.
Front-loaded Operating Spend And Ramp LagHeavy, front-loaded SG&A and R&D spend to expand commercial coverage increases near-term cash pressure and requires sustained sales acceleration to achieve operating leverage. New hires need ramp time, so these structural investments raise the risk of elevated burn before full productivity.
Fennec Pharmaceuticals News
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$7.59 and its highest was C$16.00 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is C$482.61M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on May 14, 2026. The company reported C$0.014 earnings per share for the quarter, beating the consensus estimate of -C$0.062 by C$0.076.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.03.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,737,030 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of C$0.014 in its last earnings report, beating expectations of -C$0.062. Following the earnings report the stock price went up 36.315%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$21.73 (55.76% Upside)
C$21.73 (55.76% Upside)
Blogger Sentiment
Bullish
TSE:FRX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
54.78%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
FRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple material commercial and clinical positives: strong top-line acceleration (+73% YoY), meaningful operational traction from the Fennec HEARS hub (48% QoQ infusion increase, 80% conversion and adherence), expanded commercial reach (prescriber targets expanded from ~1,300 to >5,000) and growing clinical momentum via ISTs and ASCO visibility. Counterbalancing these positives are higher near-term operating expenses (~$14M in Q1, ~$50M expected for 2026 with front-loaded spend), some near-term cash seasonality with Q2 expected to be lower than Q1, and a missed German milestone from partner Norgine. Overall, the highlights and catalysts materially outweigh the lowlights, with management emphasizing that cash plus projected revenues should fund operations and that commercial investments are already showing early returns.View all TSE:FRX earnings summariesFRX Stock 12 Month Forecast
Average Price Target
C$21.73
▲(55.76% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―